Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 12 2020 - 07:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November 2020
Commission File No.: 001-35773
REDHILL BIOPHARMA LTD.
(Translation of registrant's name into English)
21 Ha'arba'a Street, Tel Aviv, 6473921,
Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F
[ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule
101(b)(7):
Attached hereto and incorporated by reference herein are the
following:
Exhibit 1: Registrant's press release
entitled “RedHill Biopharma Provides Q3/2020 Results and
Highlights, Including 300% Talicia Prescription Growth”.
Exhibit 2: Registrant’s condensed
consolidated interim unaudited financial information as of
September 30, 2020 and for the three and nine months then
ended.
Exhibits 1 (solely with respect to the Financial highlights for
the third quarter, ended September 30, 2020, Liquidity and Capital
Resources, Commercial Highlights, R&D Highlights, the Condensed
Consolidated Interim Statements of Comprehensive Loss, Condensed
Consolidated Interim Statements of Financial Position and Condensed
Consolidated Interim Statements of Cash Flows) and Exhibit 2 to
this Report on Form 6-K are hereby incorporated by reference into
the Company's Registration Statements on Form S-8 filed with the
Securities and Exchange Commission on May 2, 2013 (Registration No.
333-188286), on October 29, 2015 (Registration No. 333-207654), on
July 25, 2017 (Registration No. 333-219441), on May 23, 2018
(Registration No. 333-225122) and on July 24, 2019 (File No.
333-232776) and its Registration Statements on Form F-3 filed with
the Securities and Exchange Commission on February 25, 2016
(Registration No. 333-209702), on July 23, 2018 (File No.
333-226278) and on July 24, 2019 (File No. 333-232777)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
REDHILL
BIOPHARMA LTD. |
|
|
(the
"Registrant") |
|
|
|
|
|
|
Date: November 12, 2020 |
|
By: /s/
Dror Ben-Asher |
|
|
Dror
Ben-Asher |
|
|
Chief
Executive Officer |
|
|
|
Redhill Boipharma (NASDAQ:RDHL)
Historical Stock Chart
From Dec 2020 to Jan 2021
Redhill Boipharma (NASDAQ:RDHL)
Historical Stock Chart
From Jan 2020 to Jan 2021